No abstract
Objectives: This study sought to assess 18 F-fludarabine ( 18 F-FLUDA) PET/ CT's ability in differentiating primary central nervous system lymphomas (PCNSLs) from glioblastoma multiformes (GBMs). Patients and Methods: Patients harboring either PCNSL (n = 8) before any treatment, PCNSL treated using corticosteroids (PCNSLh; n = 10), or GBM (n = 13) were investigated with conventional MRI and PET/CT, using 11 C-MET and 18 F-FLUDA. The main parameters measured with each tracer were SUV T and T/N ratios for the first 30 minutes of 11 C-MET acquisition, as well as at 3 different times after 18 F-FLUDA injection. The early 18 F-FLUDA uptake within the first minute of injection was equally considered, whereas this parameter was combined with the later uptakes to obtain R FLUDA 2 and R FLUDA 3 ratios. Results: No significant differences in 11 C-MET uptakes were observed among PCNSL, PCNSLh, and GBM. With 18 F-FLUDA, a clear difference in dynamic GBM uptake was observed, which decreased over time after an early maximum, as compared with that of PCNSL, which steadily increased over time, PCNSLh exhibiting intermediate values. The most discriminative parameters consisting of R FLUDA 2 and R FLUDA 3 integrated the early tracer uptake (first 60 seconds), thereby provided 100% specificity and sensitivity. Conclusions: 18 F-FLUDA was shown to likely be a promising radiopharmaceutical for differentiating PCNSL from other malignancies, although a pretreatment with corticosteroids might compromise this differential diagnostic ability. The diagnostic role of 18 F-FLUDA should be further investigating, along with its potential of defining therapeutic strategies in patients with PCNSL, while assessing the treatments' effectiveness.
Background: The purpose of the presented work is to evaluate the last decade’s experience in surgical management of central neurocytoma (CN) and elucidate on the treatment strategies and new options. Methods: The current series consists of the remaining 125 patients (70 females and 55 males) operated on during the past decade from 2008 to 2018. Most tumors were resected through transcortical (n = 76, 61%), or transcallosal (n = 40, 32%) approaches. In 5 (4%) patients with predominantly posterior location of the tumor, non-dominant superior parietal lobule approach was utilized. Both approaches (transcortical + transcallosal) were used in 4 (3%) of cases. Seven consecutive patients with large CN underwent prophylactic intraventricular stenting to prevent hydrocephalus. Results: Gross total resection was achieved in 45 patients (36%), subtotal resection (STR) in 40 (32%) cases. After surgery, 63 (50%) patients had neurocognitive problems, including disorientation, attention deficit, global amnesia, short-term memory deficits, and perceptual motor and social cognition problems. A total of 26 patients (21%) had postoperative hemorrhage in the resection bed. Obstructive hydrocephalus was noted in 25 (20%) patients. The entrapment of the occipital and/or temporal horns was observed in seven cases. None of the seven patients with prophylactic intraventricular stents required shunting. Conclusion: Although high rates of gross total or STR can be expected, the mortality and morbidity remain significant even in the modern neurosurgical era. Prophylactic intraventricular stenting in patients with large posteriorly located tumors with hydrocephalus may prevent ventricular entrapment and shunting. The main risk factors for recurrence are presence of residual disease and Ki-67 index over 5%. Recurrent symptomatic tumors should be treated surgically, whereas asymptomatic progression can be managed with stereotactic radiosurgery. Both treatment modalities are associated with low risk of complications and high tumor control rates.
Background: The use of magnetic resonance (MR) tractography in neurosurgery is becoming an increasingly common practice for noninvasive imaging of white matter pathways. The most common method of tract reconstruction is the deterministic algorithm of diffusion tensor magnetic resonance imaging (MRI). However, this method of reconstructing pathways has a number of significant limitations. The most important of them are the lack of the possibility of visualizing the intersecting fibers, the complexity of building tracts in the area of perifocal edema and in the immediate vicinity of the tumor borders. The method of MR tractography, based on obtaining a diffusion image with a high angular resolution (High Angular Resolution Diffusion Imaging, HARDI), using the constrained spherical deconvolution (CSD) algorithm for post-processing of data, makes it possible to avoid these disadvantages. Relatively recently, a new algorithm, Single-Shell 3-Tissue CSD (SS3TCSD), has been proposed for processing HARDI data, which has the potential to improve the reconstructing of pathways in the area of perifocal edema or edema-infiltration.Aim: To evaluate the potential of the new SS3TCSD algorithm compared to ST-CSD (Single-Tissue CSD) in the imaging of the optic radiation and visual tracts in patients with gliomas.Materials and methods: Diffusion and routine brain MRI was performed in 10 patients with newly diagnosed cerebral gliomas, followed by reconstruction of the optic radiation and visual tracts. We compared new algorithms for postprocessing MR tractography (ST-CSD and SS3TCSD) in imaging of the optic tract and visual radiation in patients with brain gliomas affecting various parts of the visual system.Results: The SS3T-CSD method showed a lower mean percentage of false positive tracts compared to the ST-CSD method: 19.75% for the SS3T-CSD method and 80.32% for the ST-CSD method in cases of proximity of the tumor to the tracts, 5.27% for the SS3T-CSD method and 25.27% for the STCSD method in cases of reconstructing tracts in healthy white matter.Conclusion: The SS3T-CSD method has a number of advantages over ST-CSD and allows for successful imaging of the optic pathways that have a complex structure and repeatedly change direction along their course.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.